Immune system Double-Punch tested against spreading kidney cancer
NCT ID NCT02964078
Summary
This study tested a combination of two drugs, pembrolizumab (Keytruda) and interleukin-2 (Proleukin), to treat kidney cancer that had spread. The goal was to see if using these two immune-boosting drugs together could better control the cancer. The trial involved 27 adults with a specific type of advanced kidney cancer to measure how well the tumors responded to the treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.